Cibus (CBUS) AI Stock Analysis

• Market Cap: $86.80M
• Dividend Yield: N/A
• Average Volume (3M): 600.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.15
• Revenue Growth: 63.66%
• EPS Growth: 36.72%
• Country: US
• Employees: 157
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.61
• Shares Outstanding: 52,540,527
• 10 Day Avg. Volume: 1,378,741
• 30 Day Avg. Volume: 600,304
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 3.17
• Enterprise Value/Revenue: 56.80
• Enterprise Value/Gross Profit: 56.80
• Enterprise Value/Ebitda: -1.05
• 1Y Price Target: $20.00
• Price Target Upside: 1150.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 48 Neutral
• Price Target: $1.50 ▼(-6.25% Downside)

Cibus's overall stock score is primarily impacted by its financial performance, which is the weakest aspect due to ongoing profitability and cash flow challenges. The earnings call provided some optimism with future revenue potential and strategic cost management, but valuation remains poor. Technical analysis shows moderate strength, but long-term trends are concerning.

Positive Factors

Revenue Growth Potential

The development of rice herbicide traits with significant revenue potential indicates a strong future revenue stream, enhancing market position and long-term growth prospects.

Regulatory Advances

Regulatory acceptance of gene-editing technologies supports Cibus's market expansion and product commercialization, reinforcing its competitive advantage in biotechnology.

Cost Management

Effective cost management through reduced expenses enhances operational efficiency, supporting long-term financial stability and profitability.

Negative Factors

Profitability Challenges

Ongoing net losses highlight persistent profitability challenges, which could impede financial health and require strategic adjustments to achieve sustainability.

Cash Flow Concerns

Negative operating cash flow indicates potential liquidity issues, limiting the company's ability to invest in growth initiatives and manage financial obligations.

EU Regulatory Delays

Delays in EU regulatory processes could hinder market entry and revenue realization in key regions, affecting long-term strategic goals and market expansion.

Cibus Business Overview & Revenue Model

Company Description

Cibus (CBUS) is a biotechnology company specializing in the development of innovative agricultural solutions, particularly focusing on crop protection and enhancement through its proprietary gene-editing technology. The company operates primarily in the agricultural sector, offering products that aim to improve crop yields, enhance resistance to pests and diseases, and reduce the need for chemical pesticides. Cibus is committed to sustainable agriculture practices and works to provide farmers with tools that are both effective and environmentally friendly.

How the Company Makes Money

Cibus generates revenue through the commercialization of its gene-edited agricultural products, which include seeds and crop traits that improve performance and resilience. The company typically licenses its technology to agricultural firms, receiving upfront fees and ongoing royalties based on product sales. Key revenue streams include partnerships with large agricultural companies, which allow Cibus to leverage their distribution networks and market access. Additionally, Cibus may benefit financially from grants and collaborations with research institutions focused on agricultural innovation.

Cibus Financial Statement Overview

Summary

Cibus is experiencing financial difficulties with persistent net losses and negative cash flows. Despite some revenue growth, high debt levels and negative profitability margins indicate a precarious financial position.

Income Statement

Cibus shows a pattern of increasing revenue in the TTM with a 11.5% growth from the previous annual period. However, the company continues to face significant challenges with profitability, as evidenced by a negative EBIT margin and net profit margin. The gross profit margin is positive, but the overall financial health is weakened by substantial net losses.

Balance Sheet

The company's balance sheet indicates a high debt-to-equity ratio, showing a heavy reliance on debt financing. The return on equity remains negative, reflecting ongoing net losses. However, the equity ratio is relatively stable, suggesting some level of balance sheet strength.

Cash Flow

Cibus has a negative free cash flow, which has deteriorated further in the TTM. The operating cash flow to net income ratio is negative, indicating operational challenges in generating cash. While financing activities provide some cash inflow, the continuous negative free cash flow poses a risk to financial sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.85M	4.26M	1.82M	157.00K	25.99M	23.85M
Gross Profit	4.85M	4.26M	1.42M	-1.38M	-2.57M	-11.28M
EBITDA	-262.49M	-241.63M	-314.58M	-15.21M	-25.43M	-41.53M
Net Income	-275.33M	-251.39M	-267.63M	-16.89M	-29.20M	-44.84M
Balance Sheet
Total Assets	346.20M	350.07M	544.41M	22.42M	37.19M	63.33M
Cash, Cash Equivalents and Short-Term Investments	36.46M	14.43M	32.70M	3.43M	13.82M	29.00M
Total Debt	35.42M	36.29M	24.62M	13.54M	17.88M	19.76M
Total Liabilities	271.72M	252.24M	206.12M	15.19M	23.06M	26.45M
Stockholders Equity	72.12M	92.16M	293.47M	7.23M	14.13M	36.88M
Cash Flow
Free Cash Flow	-53.74M	-58.85M	-50.53M	-20.88M	-19.31M	-45.46M
Operating Cash Flow	-52.95M	-58.04M	-46.21M	-19.36M	-18.81M	-43.67M
Investing Cash Flow	-795.00K	-808.00K	55.06M	-1.52M	11.20M	-13.48M
Financing Cash Flow	60.18M	40.60M	20.32M	9.99M	3.74M	15.41M

Cibus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Positive. The current price of 1.6 is above the 20-day moving average (MA) of 1.54, above the 50-day MA of 1.43, and below the 200-day MA of 1.85, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 54.78 is Neutral, neither overbought nor oversold. The STOCH value of 53.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBUS.

Cibus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	―	$84.20M	-0.76	-69.96%	―	-99.64%	-59.17%
CRVO	―	$65.23M	-2.70	-54.21%	―	-19.44%	-492.39%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CBUS	―	$86.80M	-0.15	-160.72%	―	63.66%	36.72%
XFOR	―	$320.03M	-0.27	-207.22%	―	5721.31%	-671.01%
ABVC	―	$70.63M	―	-39.93%	―	186.84%	89.16%
OKYO	―	$103.05M	―	―	―	―	―

Cibus Corporate Events

Cibus Appoints Carlo Broos as Chief Financial Officer

Cibus, Inc. has appointed Cornelis (Carlo) Broos as its Chief Financial Officer, effective retroactively from September 18, 2025. Mr. Broos, who has been with the company since 2011, previously served as the Interim CFO and has extensive experience in finance and accounting. This appointment is accompanied by an Executive Employment Agreement that outlines his compensation and severance benefits, reflecting the company’s commitment to strengthening its financial leadership.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus Appoints Kimberly A. Box to Board

On September 11, 2025, Cibus, Inc. appointed Kimberly A. Box to its board of directors. Ms. Box will serve on several committees, including the Compensation Committee, Nominating and Corporate Governance Committee, and a special committee evaluating strategic alternatives to maximize shareholder value. Her extensive experience includes roles at Gatekeeper Innovation, Hewlett Packard, and various other boards, bringing valuable expertise to Cibus. The appointment reflects Cibus’s commitment to enhancing its governance and strategic direction, potentially impacting shareholder value positively.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus, Inc. Earnings Call: Progress Amidst Challenges

Cibus, Inc. Earnings Call: Progress Amidst Challenges

Cibus, Inc. Reports Q2 2025 Financial Results

Cibus, Inc. is a leading agricultural technology company specializing in developing and licensing plant traits to seed companies, focusing on productivity and sustainability in the agricultural sector. In its latest earnings report, Cibus highlighted its strategic focus on rice herbicide tolerance traits and sustainable ingredients programs, with significant progress in commercialization efforts. The company reported a net loss of $26.6 million for the second quarter of 2025, a slight improvement from the previous year, attributed to cost reduction initiatives. Cibus successfully raised $27.5 million through a public offering, extending its cash runway as it advances towards revenue generation. Looking forward, Cibus remains optimistic about its commercialization prospects, particularly in Latin America and the U.S., and continues to benefit from a supportive global regulatory environment for gene editing technologies.